Shares of Abbott Laboratories (NYSE:ABT) ended Tuesday session in green amid volatile trading. The shares closed up +0.07 points or 0.17% at $42.16 with 1.47 Billion shares getting traded. Post opening the session at $42.10, the shares hit an intraday low of $41.80 and an intraday high of $42.32 and the price vacillated in this range throughout the day. The company has a market cap of $61.67 Billion and the numbers of outstanding shares have been calculated to be 1.47 Billion shares.
Abbott Laboratories (ABT) announced that it will present at the Wells Fargo 2016 Healthcare Conference on Wednesday, Sept. 7, 2016. Brian Yoor, senior vice president, finance and chief financial officer, will present at 7:45 a.m. Central time.
A live audio webcast will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com.
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Tuesday session in green amid volatile trading. The shares closed up +0.71 points or 2.47% at $29.47 with 341.19 million shares getting traded. Post opening the session at $29.02, the shares hit an intraday low of $28.68 and an intraday high of $29.77 and the price vacillated in this range throughout the day. The company has a market cap of $9.92 Billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
On Sept. 6, 2016 Valeant Pharmaceuticals International, Inc. (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) announced the U.S. commercial launch of RELISTOR®(methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016 .
“We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC,” said Joseph C. Papa , Chief Executive Officer of Valeant. “This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant’s continued commitment to delivering innovative products that improve people’s lives.”
In addition, RELISTOR Tablets will be highlighted during poster presentations at PAINWeek, the largest U.S. pain conference for frontline clinicians, in Las Vegas, Nevada , from September 6-10 . The posters will include the following:
- Webster LR, Harper JR, Israel RJ. “Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain taking concomitant methadone.” PAINWeek Poster, public viewing begins on Thursday, September 8 at 12:30 p.m. PT .
- Webster LR, Harper JR, Israel RJ. “Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.” PAINWeek Poster, public viewing begins on Thursday, September 8 at 12:30 p.m. PT .